Last reviewed · How we verify
Talphera, Inc — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Placebo Sufentanil NanoTab PCA System | Placebo Sufentanil NanoTab PCA System | phase 3 | Opioid analgesic | Mu-opioid receptor (μ-OR) | Pain Management | |
| morphine IV PCA | morphine IV PCA | phase 3 | opioid | mu-opioid receptor | Pain management |
Therapeutic area mix
- Pain Management · 1
- Pain management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 1 shared drug class
- Ajay Wasan, MD, Msc · 1 shared drug class
- Alza Corporation, DE, USA · 1 shared drug class
- Archimedes Development Ltd · 1 shared drug class
- Asbjørn Mohr Drewes · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- BioDelivery Sciences International · 1 shared drug class
- AdventHealth · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Talphera, Inc:
- Talphera, Inc pipeline updates — RSS
- Talphera, Inc pipeline updates — Atom
- Talphera, Inc pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Talphera, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/talphera-inc. Accessed 2026-05-16.